SLC40A1 and breast cancer: Studies have reported that the expression of the iron efflux pump, Fpn1, is decreased or absent in breast cancer, prostate cancer, hepatocellular carcinoma and leukemia, although these changes were not seen in brain or esophageal cancers [38–40].